Source: Michael King, JP Morgan (9/5/13)
Trial Results Set Up DURECT Corp. for 'Exciting Year'
Source: The Life Sciences Report (04/26/2017)
read more >
VistaGen's Fast-Acting Antidepressant Targets Multibillion-Dollar Market
Good Epilepsy Data from Zynerba Pharmaceuticals Would Set Stage for Pivotal Trials
2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market
Source: The Life Sciences Report (04/19/2017)
RXi Pharmaceuticals Receives Japanese Patent for RNAi Platform
Source: The Life Sciences Report (04/12/2017)
Five Companies with Favorable Risk/Reward Profiles from the AlphaNorth Capital Conference
String of Positive Trial Results Boosts RepliCel's Profile
Cash-Rich Zynerba's Synthetic Cannabinoid Product Line Ready to Rumble
Source: The Life Sciences Report (04/05/2017)
VistaGen Therapeutics Advances New-Generation Antidepressant Approved by European Patent Office
Four Biotech Mid-Caps Fund Manager Eden Rahim Believes Have Favorable Catalysts
© 2017 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.